Pharma News, 2026

Nucleome Therapeutics nominates NTP464, a first-in-class antibody agonist for autoimmune diseases, discovered via its 3D genetics MCC platform.

Nxera Pharma announces positive Phase III results for daridorexant (Quviviq) in South Korea. Plans for marketing authorization application in Q1 2026.

Chinese medicine exports reached $100.9B in 2025. Out-licensing deals hit a record $135.7B. New trade platforms boost ties with ASEAN and global markets.

Vibrant Therapeutics secures $61m from Pfizer Ventures to advance VIB305, a masked T-cell engager for EGFR solid tumours, and enters US trials.

Axsome initiates FORWARD Phase III trial evaluating AXS-14 (esreboxetine) for fibromyalgia management, affecting 17 million in the US.

New phase IV data show Shexiang Tongxin Dropping Pill (STDP) improves coronary blood flow (CSFP) in angina patients by reducing CTFC with high safety.

New analysis from Phase III trials shows J&J’s Caplyta (lumateperone) nearly doubles remission likelihood in MDD patients. Explore clinical data and market outlook.

Discover new preclinical data for elunetirom presented at ACNP. Learn how this novel CNS-TRβ agonist enhances neuroplasticity and synaptic strengthening for MDD and bipolar depression.

Gelteq's oral gel platform shows significantly increased CBD bioavailability in preclinical studies, offering a safer, more predictable delivery system for medicinal cannabis.

Explore the potential of blue pharmaceuticals. Learn about the challenges of marine drug supply, the success of eribulin, and the future of microalgal biorefineries.

Explore critical Phase 3 clinical trial data reports and regulatory filings expected in 2026, covering vaccines for Lyme disease, treatments for HCV, CRAB infections, and HIV.

MANE strengthens its flavor and fragrance innovation by acquiring ChemoSensoryx Biosciences, a leader in molecular chemosensory receptor research.